Aldardeer, N. F., Labban, H. M., Alhuthil, R. T., Aljahdali, S. H., Alharbi, M. H., Alharbi, R. A., . . . Almangour, T. A. (2024). Effectiveness of traditional non-carbapenem β-lactams vs. novel β-lactams for the treatment of carbapenem-resistant Pseudomonas aeruginosa. BMC Infectious Diseases, 24(1), 1. https://doi.org/10.1186/s12879-024-10365-5
Chicago-referens (17:e uppl.)Aldardeer, Namareq F., Hatun M. Labban, Raghad T. Alhuthil, Seham H. Aljahdali, Moataz H. Alharbi, Riham A. Alharbi, Mohammed I. Al Musawa, Abdulrahman A. Almalki, och Thamer A. Almangour. "Effectiveness of Traditional Non-carbapenem β-lactams Vs. Novel β-lactams for the Treatment of Carbapenem-resistant Pseudomonas Aeruginosa." BMC Infectious Diseases 24, no. 1 (2024): 1. https://doi.org/10.1186/s12879-024-10365-5.
MLA-referens (9:e uppl.)Aldardeer, Namareq F., et al. "Effectiveness of Traditional Non-carbapenem β-lactams Vs. Novel β-lactams for the Treatment of Carbapenem-resistant Pseudomonas Aeruginosa." BMC Infectious Diseases, vol. 24, no. 1, 2024, p. 1, https://doi.org/10.1186/s12879-024-10365-5.
